Clinical trials progress of Ebola vaccines
WANG Yu-xiao
LI Jing-xin
WANG Yang
ZHU Wen-bo
ZHU Feng-cai
Abstract：Ebola virus disease(EVD) is formerly known as Ebola hemorrhagic fever. No specific drugs and treatments against Ebola disease are available currently. Vaccination is considered as the most promising and effective method to control EVD. So far, several candidate vaccines have been developed and evaluated through clinical trials, including recombinant vesicular stomatitis virus-based vaccine expressing Zaire ebolavirus (rVSV-ZEBOV), replication-defective recombinant chimpanzee adenovirus type 3-vectored Ebola vaccines (cAd3-EBO or ChAd3-EBO-Z), replication-defective recombinant human adenovirus type 5 vector-based Ebola virus vaccines (Ad5-EBOV) and human parainfluenza virus type 3-based Ebola vaccine (HPIV3). Among them, ChAd3-EBO-Z and Ad5-EBOV have demonstrated good safety and immunogenicity profile. rVSV-ZEBOV is the most promising candidate vaccine, which has showed a significant protection against EVD in a phase Ⅲ clinical trial. However, the safety evaluation of the rVSV-ZEBOV has still raised some concerns. This paper aims to review the important development of Ebola vaccines since the outbreak of Ebola in 2014, and discusses the issues and challenges remained together with the trends in the future.
Keywords：Ebola virusvaccineclinical trialefficacysafety
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 82-85 )